MedTrace Logo

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

NCT03572972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64684

Last updated 2023-04-06

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health claims database.

Conditions

Interventions

DRUG

Apixaban

Treatment for NVAF patients

DRUG

Dabigatran

Treatment for NVAF patients

DRUG

Rivaroxaban

Treatment for NVAF patients

DRUG

warfarin

Treatment for NVAF patients

DRUG

Antiplatelets

Treatment for NVAF patients

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2018-12-20
Completion
2018-12-20
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572972 on ClinicalTrials.gov